Shortness of Breath: Anxiety or Lung Health Issue? We Break it Down - American Lung Association

Skip to Content Subscribe FAQ My Account Manage My Subscriptions News Local News Public Service National World True Crime Weather Archives Tariffs Opinion Editorials Letters Submit a Letter Columnists Submit an Opinion Column Food Local Food Reviews Arts Local Arts Music Local Reviews Movies Television TV Listings Books Celebrity Cappies Public Service Defence Watch Fixing Byward Sports Ottawa Senators NHL PWHL More Hockey Junior Hockey Local Sports Ottawa Redblacks CFL NFL Baseball Basketball NBA Tennis Golf Life Savings Newsletters Lives Told Tails Told Shopping Ottawa Citizen Store Puzzmo Obituaries Place an Obituary Place an In Memoriam Longreads Diversions Comics Puzzles New York Times Crossword Contests Healthing ePaper Driving Vehicle Research Reviews News Gear Guide Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Browse Listings Place an Ad Business Card Directory Celebrations Real Estate Marketplace Pet Posts and Adoptions Working Business Ads This Week's Flyers Manage Print Subscription National Capital Region's Top Employers Inside Ottawa Hospital Social Scene Profile Settings My Subscriptions My Offers

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.